CJC-1295 (No DAC) & Ipamorelin Blend: The Synergistic Secretagogue Duo
The Onyx Biolabs CJC-1295 (No DAC) / Ipamorelin Blend is a sophisticated combination of two potent growth hormone secretagogues. This dual-peptide formulation is engineered to leverage the synergistic relationship between a Growth Hormone-Releasing Hormone (GHRH) analogue and a Growth Hormone Secretagogue (GHS), specifically designed for researchers investigating enhanced endogenous hormone signaling.
Mechanism of Action: Dual-Pathway Stimulation
In research protocols, this blend is studied for its ability to maximize the amplitude of growth hormone (GH) pulses. The two compounds work via distinct but complementary pathways:
CJC-1295 (No DAC): Functions as a GHRH mimetic. It binds to GHRH receptors in the anterior pituitary to initiate the production and release of growth hormone. The “No DAC” (Drug Affinity Complex) version is specifically chosen for its shorter half-life, more closely mimicking the natural physiological spikes of human GH.
Ipamorelin: Acts as a selective Ghrelin receptor agonist. It reinforces the GH pulse by inhibiting somatostatin (the hormone that suppresses GH) and directly stimulating the pituitary to release stored GH.
Key Research Focus Areas
Hypertrophic Signaling: Investigation into the upregulation of IGF-1 and its role in cellular repair, muscle protein synthesis, and bone density.
Metabolic Efficiency: Researching the blend’s impact on basal metabolic rate, adipose tissue oxidation, and nitrogen retention.
Selective Potency: Unlike older secretagogues, Ipamorelin is highly selective; studies suggest it does not significantly impact prolactin, cortisol, or ACTH levels, making it a preferred subject for clean signaling research.
Recovery and Sleep Architecture: Evaluation of how pulsatile GH release influences circadian rhythm and deep-wave sleep recovery cycles.
Research Applications & Storage
This compound is supplied as a lyophilized powder in a 1:1 ratio (5mg/5mg) for a total of 10mg. For research protocols, it requires reconstitution with Bacteriostatic Water. Once reconstituted, the solution must be kept refrigerated at 2-8°C. Avoid agitation or vigorous shaking of the vial to maintain the structural integrity of the peptide chains.
References
Bowers, C. Y. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. The Journal of Clinical Endocrinology & Metabolism, 70(4), 975–982. https://doi.org/10.1210/jcem-70-4-975
Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536